Table 2.
Demographic and clinical characteristics of the RRMS and HC groups.
|
RRMS (n = 24) M (SD) |
HC (n = 59) M (SD) |
p-value | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 33.21 (10.75) | 29.85 (12.26) | 0.25 |
| Sex (% female) | 70.83 | 61.02 | 0.46 |
| Education (years) | 11.65 (1.65) | 12.96 (0.33) | <0.01 |
| EDSS, median (IQR) | 1.25 (1) | NA | NA |
| Disease duration (years) | 1.89 (0.92) | NA | NA |
| Disease-modifying therapies (%) | Fingolimod: 25 Natalizumab: 25 Interferon beta: 16.7 Dimethyl fumarate: 12.5 Glatiramer acetate: 8.3 Alemtuzumab: 4.2 Teriflunomid: 4.2 No treatment: 4.2 |
||
| Vocational status (%) | Employed: 83.33 Unemployed: 8.3 Student: 4.2 Unknown: 4.2 |
||
| Neuropsychological assessment | |||
| SDMT | 51.42 (10.24) | 59.67 (10.19) | <0.01 |
| PASAT 3s | 45.92 (13.65) | NA | NA |
| HADS Depression | 3.63 (3.51) | 3.39 (3.25) | 0.77 |
| HADS Anxiety | 5.04 (3.93) | 5.79 (3.58) | 0.40 |
| FSMC | 43.58 (21.31) | 43.40 (13.97) | 0.97 |
RRMS, relapsing–remitting multiple sclerosis; HCs, healthy controls; n, number of patients; M, mean; SD, standard deviation; SDMT, Symbol Digit Modalities Test; PASAT 3s, Paced Auditory Serial Addition Test three-second interval; EDSS, Expanded Disability Scale; HADS, Hospital Anxiety and Depression Scale; FSMC, Fatigue Scale for Motor and Cognitive Functions. IQR, interquartile range. Bold values indicate statistical significance.